References
- Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. Herceptin Adjuvant (HERA) Trial Study Team. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.Lancet 2017; 389: 1195-205. 10.1016/S0140-6736(16)32616-2
- Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. Breast 2013; 22: 152-5. 10.1016/j.breast.2013.07.029
- Mathew A, Romond EH. Systemic therapy for HER2-positive early-stage breast cancer. Curr Probl Cancer 2016; 40: 106-16. 10.1016/j.currproblcancer.2016.09.002
- Matos E, Zakotnik B, Kuhar CG. Effectiveness of adjuvant trastuzumab in daily clinical practice. Radiol Oncol 2014; 48: 403-7. 10.2478/raon-2013-0081
- Zamorano JL, Lancellotti P, Muñoz DR, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 2768-801. 10.1093/eurheartj/ehw211
- Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK, et al. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis. Medicine (Baltimore) 2016; 95: e5195. 10.1097/MD.0000000000005195
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 2005; 353: 1659-72. 10.1056/NEJMoa052306
- Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6: 557-65. 10.1016/S1470-2045(05)70251-5
- Henson KE, McGale P, Taylor C, Darby SC. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer 2013; 108: 179-82. 10.1038/bjc.2012.575
- Sardar P, Kundu A, Chatterjee S, Nohria A, Nairooz R, Bangalore S, et al. Long-term cardiovascular mortality after radiotherapy for breast cancer: a systematic review and meta-analysis. Clin Cardiol 2017; 40: 73-81. 10.1002/clc.22631
- Jacob J, Belin L, Gobillion A, Daveau-Bergerault C, Dendale R, Beuzeboc P, et al. [Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].[French]. Cancer Radiother 2013; 17: 183-90. 10.1016/j.canrad.2012.12.006
- Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-600. 10.1002/cncr.10854
- Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22: 322-9. 10.1200/JC0.2004.01.120
- Fiuza M. Cardiotoxicity associated with trastuzumab treatmentof HER2+ breast cancer. Adv Ther 2009; 26(Suppl 1): S9-17. 10.1007/s12325-009-0048-z
- Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Longterm cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006; 24: 4107-15. 10.1200/JCO.2005.04.9551
- Steel GG. Basic clinical radiobiology. 3rd edition. London: Arnold; 2002. p. 217-39.
- Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-16. 10.1056/NEJMoa0707064
- Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of streching. Endocrinology 1993; 132: 1961-70. 10.1210/endo.132.5.8477647
- Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89: 745-51.
- Marinko T, Dolenc J, Bilban-Jakopin C. Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer. Radiol Oncol 2014; 48: 105-12. 10.2478/raon-2013-0040
- Marinko T. Impact of concurrent radiotherapy and treatment with trastuzumab on cardiotoxicity of breast cancer patients. [Dissertation]. Ljubljana: Faculty of Medicine, University of Ljubljana; 2014.
- R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013. [cited 2017 Nov 15]. Available at http://www.R-project.org/
- Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99: 365-75. 10.1093/jnci/djk064
- National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2017. [cited 2017 Nov 7]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
- Ewer MS, Tan-Chiu E. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well? J Clin Oncol 2007; 25: 5532-3. 10.1200/JCO.2007.14.0657
- Giannuzzi P, Temporelli PL, Bosimini E, Silva P, Imparato A, Corrà U, et al. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol 1996; 28: 383-90. 10.1016/0735-1097(96)00163-5
- Suzuki J, Yanagisawa A, Shigejama T, Tsubota J, Yasumura T, Shimoyama K, et al. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography. Angyology 1999; 50: 37-45. 10.1177/000331979905000105
- Hall EJ, Giaccia AJ. Radiobiology for the radiologist. Chapter 20. 7th edition. Philadelphia: Lippincott Williams & Wilkins, Wolters Kluwer; 2012. p 343.